(r,r)-1-{1-[bis[3,5-bis(trifluoromethyl)phenyl]phosphino]ethyl}-2-[2-(dicyclohexylphosphino)phenyl]ferrocene (acc to cas)

Catalog No. :
ACCKDX302
CAS No. :
494227-32-6
Molecular Formula :
-
Molecular Weight :
-

IUPAC Name:-

(r,r)-1-{1-[bis[3,5-bis(trifluoromethyl)phenyl]phosphino]ethyl}-2-[2-(dicyclohexylphosphino)phenyl]ferrocene (acc to cas) structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10g98%$4884.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(r,r)-1-{1-[bis[3,5-bis(trifluoromethyl)phenyl]phosphino]ethyl}-2-[2-(dicyclohexylphosphino)phenyl]ferrocene (acc to cas)
MDL No.-
SMILES[][Fe][].C[C@H](P(C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)c3ccCc3C4=C([p](C5CCCCC5)c6cCCCC6)C=CC=C4.C7CCCC7
InChI Key(r,r)-1-{1-[bis[3,5-bis(trifluoromethyl)phenyl]phosphino]ethyl}-2-[2-(dicyclohexylphosphino)phenyl]ferrocene (acc to cas)
Synonym(r)-1-{(r)-2-[2-(dicyclohexylphosphino)phenyl]ferrocenyl}ethylbis[3,5-bis(trifluoromethyl)phenyl]phosphine;(r,r)-1-{1-[bis[3,5-bis(trifluoromethyl)phenyl]phosphino]ethyl}-2-[2-(dicyclohexylphosphino)phenyl]ferrocene (acc to cas);(R)-(+)-1-[(R)-2-(2'-Dicyclohexylphosphino phenyl)ferrocenyl] ethyldi(bis-3,5-trifluoromethylphenyl) phosphine, min. 97%;(R)-1-{(RP)-2-[2-(Dicyclohexylphosphino)phenyl]ferrocenyl}ethylbis[3,5-bis(trifluoromethyl)phenyl]phosphine >=97%;(1S)-1-[(1R)-1-[bis[3,5-bis(trifluoromethyl)phenyl]phosphino]ethyl]-2-[2-(dicyclohexylphosphino)phenyl]ferrocene (acc to CAS);(R)-(R)-cy2PPhFCHCH3P(3,5-CF3Ph)2;(R)-1-((R)-2-(2'-dicycelohexylphosphinophenyl) ferroceny1] ethyldi(bis-3,5-trifluoromethylphenyl)ph;(R)-1-{(RP)-2-[2-(Dicyclohexylphosphino)phenyl]ferrocenyl}ethylbis[3,5-bis(trifluoroMethyl)phenyl]phosphine
CAS No.494227-32-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Comments (0)